Description: Botanix Pharmaceuticals Limited, a clinical stage cannabinoid therapeutics company, develops therapeutics for serious skin diseases in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; BTX 1701, a novel product for mild acne; and BTX 1801, a novel antimicrobial. The company is based in North Perth, Australia.
Home Page: www.botanixpharma.com
D2, 661 Newcastle Street
Leederville,
WA
6007
Australia
Phone:
61 8 6555 2945
Officers
| Name | Title |
|---|---|
| Mr. Vincent P. Ippolito | MD & Exec. Chairman |
| Dr. Howie McKibbon | Chief Operating Officer |
| Dr. Henry William Bosch BA, Ph.D. | Chief Scientific Officer & Exec. Director |
| Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB | Exec. Director |
| Dr. Clarence L. Young M.D. | Chief Medical Officer |
| Ms. Lynda Berne | Head of Commercial |
| Dr. Jack Hoblitzell Ph.D. | Sr. VP of Pharmaceutical Devel. |
| Dr. Patricia S. Walker M.D., Ph.D. | Chief Medical Adviser |
| Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA | Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4761 |
| Price-to-Sales TTM: | 17.0571 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 11 |